同和药业(300636.SZ)获得欧洲药典适应性证书

Core Viewpoint - The company has received a revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production facility [1]. Group 1 - The company announced the receipt of the updated CEP for Ticagrelor active pharmaceutical ingredient [1]. - The revision of the CEP is primarily due to the establishment of a new production workshop [1]. - The effective date for the revised certificate is set for September 12, 2025 [1].